The Buerger’s Disease Market encompasses a range of therapeutic solutions designed to treat thromboangiitis obliterans, a non-atherosclerotic vascular disorder primarily affecting small- and medium-sized arteries and veins. Leading product categories include vasodilators, prostaglandin analogues, antiplatelet agents, and emerging regenerative options such as stem cell–based therapies and gene therapy interventions. Vasodilators and prostaglandin analogues work by improving peripheral blood flow and alleviating ischemic pain, while antiplatelet agents help reduce thrombus formation. Regenerative therapies harness mesenchymal stem cells and angiogenic factors to promote neovascularization and tissue repair in affected limbs, offering the potential for limb salvage and long-term functional improvement. These advanced interventions provide advantages over traditional treatments by targeting the underlying vascular occlusion and enhancing endogenous repair mechanisms.

The growing incidence of tobacco-related vascular damage, coupled with an unmet need for curative treatments, has intensified demand for innovative therapies. Clinicians and patients alike are seeking options that not only manage pain but also address disease progression and reduce amputation rates. Global adoption is further buoyed by increasing clinical research advancements and supportive reimbursement frameworks in major healthcare systems.

According to CoherentMI, The Buerger's disease market is estimated to be valued at USD 443.7 million in 2025 and is expected to reach USD 641.2 million by 2032, growing at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2032.

Key Takeaways

Key players operating in the Buerger’s Disease Market are:

-AnGes Inc.

-Mitsubishi Tanabe Pharma Corporation

-Pluristem Therapeutics Inc.

-Stempeutics Research Pvt. Ltd.

-Fuji Yakuhin Co., Ltd.

These organizations are at the forefront of product innovation, conducting extensive R&D into cell-based therapies, gene delivery platforms, and novel drug formulations. AnGes Inc. focuses on gene therapy vectors aimed at angiogenesis, whereas Mitsubishi Tanabe Pharma Corporation leverages its global distribution network to supply prostaglandin analogues and vasodilators. Pluristem Therapeutics Inc. and Stempeutics Research Pvt. Ltd. are pioneering mesenchymal stem cell solutions for peripheral ischemia, while Fuji Yakuhin Co., Ltd. offers a portfolio of conventional antithrombotic agents. Collectively, these players are driving market growth through strategic partnerships, clinical trials, and regulatory filings.

Rising demand for effective, minimally invasive treatments is fueling Buerger’s Disease Market expansion. The growing global burden of Buerger’s disease—driven by persistent tobacco use and increasing recognition of the disease in emerging economies—has created urgency for novel interventions. Patients and healthcare providers are seeking therapies that deliver sustained improvements in blood flow, pain management, and limb preservation. This heightened demand is encouraging investment in advanced manufacturing facilities and bolstering cross-border licensing agreements. Additionally, patient advocacy groups and professional societies are raising awareness about early diagnosis and treatment options, further accelerating uptake of innovative products.

‣ Get More Insights On: Buerger’s Disease Market

‣ Get this Report in Japanese Language: バージャー病市場

‣ Get this Report in Korean Language: 버거병시장